JACKSON CENTER, Pa. - Halberd Corporation's research at Mississippi State University has shown a reduction in two key markers of traumatic brain injury (TBI) in early testing of the firm's patent-pending nasal spray to mitigate the effects of TBI.
Data from preliminary testing reveals a 20% reduction in Neuron Specific Enolase and a 50% reduction in the levels of Glial Fibrillary Acid Protein compared to the control group.
NSE is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcomes of TBI. GFAP is an indicator of the induction of neuro-inflammation and is increased following TBI.
It is also thought to be an indicator of ongoing neuro-degeneration related to numerous other diseases. Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.
Dr. Russell Carr, professor at MSU's Veterinary College and lead investigator, said: Research testing the effectiveness of the novel nasal therapeutic to treat the negative effects induced by TBI "has made significant progress."
While the analysis of all regions is not complete, the "results for the cerebral cortex strongly suggest" that nasal administration of the therapeutic following a significant head impact "greatly reduces the markers for cellular damage and neuro-inflammation."
Although data is not complete, the team intends to "analyze the hippocampus as well as plan to repeat the experiment to ensure scientific validity."
Dr. Mitchell S. Felder of Halberd noted, "These are very exciting preliminary results." It is the only documented therapeutic pathophysiologic ameliorations for TBI.
The data may also aid in the treatment of brain tumors, strokes and epilepsy.
The MSU testing data is "showing the timely application of Halberd's nasal spray within hours of (TBI) can potentially mitigate factors associated with long-term neurodegeneraton, often leading to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures," said William A. Hartman, Chairman of Halberd
The research will fine tune and complete current testing protocol and cognitive testing before commencing treatment on larger animals.
"This product could have massive benefit to contact sports participants ... as well as the military and PTSD victims ... and reduce the 50,000 depression-related suicides each year in the U.S. (Halbred News 09/06/23) Halberd Corporation | Press Releases, Latest News, Updates
No comments:
Post a Comment